DALLAS, July 21, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/SOMX
SOMX's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility.
Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. On March 18, 2010, the U.S. Food and Drug Administration (FDA) notified the Company that it approved its New Drug Application (NDA) for Silenor (doxepin) 3 milligram and 6 milligram tablets for the treatment of insomnia characterized by difficulty with sleep maintenance. The Company's clinical development program for Silenor included four phase 3 clinical trials, and the primary efficacy endpoint achieved statistical significance in each trial. Its clinical trials for Silenor also demonstrated a favorable safety and tolerability profile, including a low dropout rate, an adverse event profile comparable to placebo, no clinically meaningful next-day residual effects and no evidence of amnesia, complex sleep behaviors, hallucinations, tolerance or withdrawal effects.
Message Board Search for SOMX: http://www.boardcentral.com/boards/SOMX
In the report, the analyst notes:
"SOMX recently announced that it has established a commercial team to promote its insomnia drug Silenor. The Company entered into a Professional Detailing Services Agreement with Publicis Touchpoint Solutions pursuant to which Publicis will provide SOMX with 110 sales representatives on a contract basis that will exclusively promote Silenor.
"According to CEO Pascoe, the Company continues to engage in discussions with third parties relating to the commercialization of Silenor - and believes that this specialty sales force structure and marketing plan will provide the Company with the flexibility needed to complement the promotional efforts of any strategic collaborator in the marketing of Silenor."
To read the entire report visit: http://www.microstockprofit.com/lp/SOMX
See what investors are saying about SOMX at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.